SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that it has initiated a clinical trial to evaluate higher doses of MB07803 in patients. MB07803 is Metabasis’ second-generation FBPase inhibitor product candidate for the treatment of type 2 diabetes. The trial is expected to enroll at least 40 patients.
